Year None2022202120202019201820172016 Date Latest Press Release November 12, 2019 Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019 November 7, 2019 Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update October 21, 2019 Eiger Announces Peginterferon Lambda Combination Therapy for Treatment of Chronic Hepatitis Delta Virus (HDV) Infection to be Featured in a Late-Breaking Oral Presentation at AASLD 2019 September 27, 2019 Eiger to Present at Cantor 2019 Global Healthcare Conference August 29, 2019 Eiger BioPharmaceuticals to Participate in September Conferences August 20, 2019 Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection August 8, 2019 Eiger BioPharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update August 5, 2019 Eiger BioPharmaceuticals to Participate in Investor Conferences in August June 17, 2019 Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH) June 10, 2019 Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs Pagination First page « first Previous page ‹ previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page next › Last page last »
